Breaking News, Trials & Filings

Provention Bio’s TZIELD Approved as First Treatment to Delay Onset of T1D

In a clinical trial, in Stage 2 T1D patients, TZIELD delayed the median onset of Stage 3 T1D by approximately 2 years, compared to placebo.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, received FDA approval for its Biologics License Application (BLA) for TZIELD (teplizumab-mzwv), an anti-CD3-directed antibody, as the first and only immunomodulatory treatment to delay the onset of Stage 3 T1D in adult and pediatric patients 8 years and older with stage 2 T1D.     Tzield binds to certain immune system cells to delay progression to stage 3 type 1 diabetes. Tzield...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters